Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Investors are cheering the company's strong Q3 results.

Why Insulet Stock Is Skyrocketing Today

Insulet Corporation (NASDAQ:PODD ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chief Executive Officer Wayde McMillan - Executive Vice President and Chief Financial Officer Bret Christensen - Executive Vice President and Chief Commercial Officer Conference Call Participants Jeff Johnson - Baird Travis Steed - Bank of America Securities Robbie Marcus - JPMorgan Margaret Kaczor - William Blair Larry Biegelsen - Wells Fargo Caitlyn Cronin - Canaccord Genuity Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer Chris Pasquale - Nephron Research Marie Thibault - BTIG Matthew O'Brien - Piper Sandler Matt Miksic - Barclays Operator Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Insulet Corporation (PODD) Q3 2022 Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of 164.71% and 9.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Q3 Earnings and Revenues Beat Estimates

Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1)

Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout November

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out for

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2022 on November 3, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor

Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received CE marking under the European Medical Device Regulation for its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes. “There is tremendous enthusiasm for Omnipod 5 from the global diabetes community, and we are thrilled

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.

3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was orig

Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

Insulet Corporation (NASDAQ:PODD ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chief Executive Officer Wayde McMillan - Executive Vice President and Chief Financial Officer Bret Christensen - Executive Vice President and Chief Commercial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JP Morgan Travis Steed - Bank of America Steve Lichtman - Oppenheimer Chris Pasquale - Nephron Research Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Margaret Kaczor - William Blair Jayson Bedford - Raymond James Brian Kennedy - Cowen Matthew O'Brien - Piper Sandler Jeff Johnson - Baird Operator Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Insulet Corporation (PODD) CEO Jim Hollingshead on Q2 2022 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2022. Second Quarter Financial Highlights: Second quarter 2022 revenue of $299.4 million, up 13.8%, or 17.7% in constant currency1, compared to $263.2 million in the prior year, exceeds the guidance range of 12% to 15% in constant currency Total

Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Omnipod® 5 Automated Insulin Delivery (AID) System (Omnipod 5) is now fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes. “With the significant demand for our tubeless AID system and impressive clinical outcomes, we continue to exp

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System

Insulet presents with compelling near-term upside capture over the coming 4-6 months. We estimate the stock to continue re-rating to the upside, based on a confluence of market, fundamental and technical factors.

Insulet: Bullish Factors For Portfolio Inclusion

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor R

Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022

Bruker

Etsy

Marriott

SolarEdge Technologies

10X Genomics

These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.

7 Stocks to Buy That Could Make You a Millionaire

Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.

Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) study results for very young children with type 1 diabetes. Omnipod 5, the first tubeless, wearable automated insulin delivery (AID) system in the U.S., significantly improved time in range and reduced HbA1c in children aged 2 through 5.9

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.

Insulet (PODD) to Expand Base in Malaysia With New Facility

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair & Company 42nd Annual Growth Stock Conference in Chicago on Wednesday, June 8, 2022, at 9:00 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the audio webcast will also be avai

Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host a groundbreaking ceremony for its new manufacturing facility in Malaysia, further strengthening its global manufacturing capabilities. “We are taking an important step to further diversify globally and ensure our valued customers continue to have uninterrupted access to our life-changing products,” said C

Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia

DexCom

Shares of DexCom Inc. DXCM, +5.35% surged 8.1% to pace the S&P 500's SPX, -0.37% premarket gainers, after the diabetes care company said it was not currently in "active discussions" regarding a merger. The stock has been dragged down over the past week, closing at a two-year low on Thursday, after Bloomberg reported that DexCom was in talks to buy Insulet Corp. PODD, -10.93% , a maker of insulin-infusion systems.

News for Insulet Stock (PODD)